Fibroma medical therapy: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 7: | Line 7: | ||
At present, there are no definitive agents for long-term medical treatment of uterine fibroma approved by Food and Drug Administration (FDA). But however, there are some agents that can be used in the management of this common benign tumor. | At present, there are no definitive agents for long-term medical treatment of uterine fibroma approved by Food and Drug Administration (FDA). But however, there are some agents that can be used in the management of this common benign tumor. | ||
====Gonadotropin-Releasing Hormone Analogues==== | |||
Gonadotropin-releasing hormone analogues can effectively reduce uterine leiomyoma volume, menorrhagia(heavy menstrual bleeding), and also stabilize hemoglobin levels by inducing an iatrogenic reversible menopause. Leuprolide, Buserelin, Nafarelin, Deslorelin, Histrelin, Goserelin, Tryptorelin | |||
Revision as of 13:44, 17 June 2019
overview
Medical therapy depends on the type of fibroma.
Medical therapy
Uterine fibroma
At present, there are no definitive agents for long-term medical treatment of uterine fibroma approved by Food and Drug Administration (FDA). But however, there are some agents that can be used in the management of this common benign tumor.
Gonadotropin-Releasing Hormone Analogues
Gonadotropin-releasing hormone analogues can effectively reduce uterine leiomyoma volume, menorrhagia(heavy menstrual bleeding), and also stabilize hemoglobin levels by inducing an iatrogenic reversible menopause. Leuprolide, Buserelin, Nafarelin, Deslorelin, Histrelin, Goserelin, Tryptorelin